FindTrial
Sign In

A Radiomics-based nomogram for Stratifying bladder cancer of Receiving Neoadjuvant Chemotherapy

A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From neoadjuvant chemotherapy of Bladder cancer Based on a Radiomics-based Nomogram

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015101
Enrollment
Unknown
Registered
2018-03-07
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

neoadjuvant chemotherapy group:chemotherapy combining gemcitabine and cisplatin for 6 weeks and receive radical cystectomy
non-neoadjuvant chemotherapy group:receive radical cystectomy without neoadjuvant chemotherapy

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The informed consent has been obtained from the patient; 2. With confirmed diagnosis of BCa (T2-T4a); 3. With moderate/good ECOG health rating (PS) 0-1 score.

Exclusion criteria

Exclusion criteria: 1. With bad compliance or contraindication to enrollment; 2. Pregnant woman or lactating woman; 3. With contraindication to receive neoadjuvant chemotherapy.

Design outcomes

Primary

MeasureTime frame
Disease free survival;—

Secondary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactTianxin Lin

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

lintx@mail.sysu.edu.cn+86 13724008338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026